New diabetes pill put to the test: does food change how it works?
NCT ID NCT07511010
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial in 28 healthy Chinese adults tests a new fixed-dose combination pill for type 2 diabetes. One part checks whether a high-fat meal changes how much drug gets into the blood. The other part looks at drug levels after taking the pill daily for 10 days. The goal is to gather safety and dosing information, not to treat diabetes yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Chiglitazar/Metformin extended-release tablets
- What this could lead to
- If successful, this study will show how to best take this new diabetes pill (with or without food) and confirm the right dosing schedule for future trials.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures drug levels and safety, not whether the drug actually controls diabetes. Results may not predict real-world effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Inflammatory diet tame type 2 diabetes?
- New diabetes combo pill aims to beat single drugs in major trial
- New combo therapy aims to improve diabetes management
- New triple therapy aims to protect kidneys in diabetes patients
- New combo diabetes pill tested in healthy volunteers
- New Triple-Drug diabetes pill aims for better blood sugar control